Cytokine Release Syndrome Evaluation Service
Creative Biolabs provides a definitive safety roadmap for your immunotherapy pipeline by transforming complex biological risks into actionable data. We don't just provide raw numbers; we offer a decision-making framework that identifies the "sweet spot" between therapeutic efficacy and manageable toxicity. By characterizing the GM-CSF/IL-6 axis and the "bystander effect," we help you select leads with the lowest risk of severe CRS and ICANS. Our evaluation ensures that molecular initiating events (MIEs) are caught early, preventing costly late-stage clinical failures.
Introduction to CRS Pathophysiology
Cytokine release syndrome (CRS) is a systemic inflammatory response triggered by the rapid activation and expansion of immune effector cells. Unlike acute "cytokine storms" associated with immediate antibody infusion, CRS typically presents with a delayed onset (1–14 days), reflecting the proliferation of antigen-specific T cells. Recent clinical literature emphasizes that while IL-6 is the central mediator of systemic symptoms like fever and hypotension, GM-CSF plays a critical role in myeloid cell recruitment across the blood-brain barrier, driving neurotoxicity (ICANS). Creative Biolabs integrates these mechanistic insights into every evaluation, ensuring your therapy is tested against the most current scientific standards.
Comprehensive Analytical Solutions for CRS Evaluation
To address the multifaceted nature of immune-mediated toxicity, Creative Biolabs offers a diverse portfolio of analytical solutions. These services are designed to characterize the inflammatory potential of your therapeutic candidates across different biological compartments.
Multiplexed Cytokine Quantification
We provide simultaneous quantification of 40+ cytokines and chemokines. This allows for the identification of signature inflammatory profiles and the determination of cytokine release kinetics with picogram-level sensitivity.
Endothelial Activation & Vascular Leakage Assays
Severe CRS is characterized by endothelial dysfunction. We offer specialized assays to measure biomarkers of vascular compromise, providing a predictive window into potential Grade 3 or 4 clinical events.
Advanced ICANS & BBB Integrity Modeling
Utilizing high-resolution in vitro blood-brain barrier (BBB) models and humanized neuro-inflammation mouse models, we evaluate the risk of neurotoxicity. Our focus on GM-CSF-driven myeloid recruitment provides unique insights into the mechanisms of ICANS.
Safety-by-Design Construct Screening
We provide comparative analysis of various CAR-T signaling domains (e.g., CD28 vs. 4-1BB) and bispecific formats to determine which architectures provide the safest inflammatory profile without compromising anti-tumor potency.
Target-Dependent & Independent Activation Profiling
Our assays distinguish between "on-target" cytokine release and non-specific, "off-target" activation triggered by high drug concentrations or Fc-receptor interactions, ensuring a comprehensive understanding of your drug's safety margins.
Unlock High-Resolution Safety Insights – Request a Specialized Assay Quote
Workflow
Our evaluation process is a structured, phase-gate approach designed to integrate seamlessly into your research and development lifecycle, providing granular insights at every stage of development.
Publication
This review synthesizes current knowledge on cytokine networks driving CRS after CAR T cell therapy. It details cellular and molecular pathways involving key cytokines, including IL-1, IL-6, IFN-γ, TNF-α, and GM-CSF, describing their cellular sources, signaling mechanisms, and effects on target tissues. By bridging basic cytokine biology with clinical manifestations and therapeutic strategies, the authors provide a comprehensive framework for understanding CRS pathophysiology to support the development of safer CAR T cell therapies.
Fig.1 CAR T cell-derived cytokines engage macrophage surface receptors. 1
Why Choose Us
Creative Biolabs stands at the intersection of advanced immunology and practical biotechnology. Our unique advantage lies in our ability to model the "bystander effect"—the process where therapeutic cells trigger host macrophages to release massive amounts of IL-6. By targeting this mechanism pre-clinically, we provide a more accurate prediction of patient risk than standard assays. Our platform supports the latest breakthroughs in CRS management, including the evaluation of GM-CSF knockout (CRISPR/Cas9) constructs and the synergy of small molecule inhibitors like Ruxolitinib. With over two decades of experience and a track record of supporting successful filings, Creative Biolabs is the partner of choice for developers seeking "safety-by-design" lead optimization.
Experience the Creative Biolabs Advantage - Get a Quote Today
FAQs
How do you distinguish between CRS and ICANS in your models?
We utilize specific endothelial activation markers and BBB-on-a-chip models to track the migration of inflammatory cells into the CNS, allowing us to differentiate between systemic inflammation and neuro-specific risks.
Can you evaluate CRS risk for non-T-cell therapies?
Yes, our platforms are highly adaptable and have been used to evaluate oncolytic viruses, mRNA-LNP therapies, and other immune-modulating modalities.
Do you offer construct optimization if high risk is detected?
Absolutely. We can support CRISPR-mediated knockouts or the addition of "suicide genes" and inhibitory CAR (iCAR) systems to help create a safer therapeutic profile.
Customer Review
-
Superior Predictive Value
Using Creative Biolabs' CRS evaluation in our research has significantly facilitated the selection of our lead CAR-T candidate. Their whole-blood assay was much more predictive of clinical cytokine spikes than standard PBMC models. - Dr. J**on S -
Exceptional ICANS Insight
The focus on the GM-CSF axis helped us understand why our previous constructs were causing neuroinflammation. The high-resolution BBB modeling provided the tangible data we needed for our board review. - Dr. Mar*** A
Related Services
Next CAR-T In Vivo Animal Testing
Creative Biolabs provides GLP-compliant in vivo pharmacology and toxicology. We evaluate biodistribution, CRS risk, and anti-tumor efficacy to ensure clinical predictability for your CAR-T/CGT products.
Learn More →Immunophenotyping based Nanomedicine Services
Creative Biolabs offers nanomaterial and EV immunophenotyping to optimize targeted delivery and biocompatibility. We utilize high-resolution flow cytometry to mitigate off-target effects and accelerate personalized nanomedicine development.
Learn More →Contact Us
Creative Biolabs offers the industry's most comprehensive suite of CRS and ICANS evaluation tools, combining deep mechanistic understanding with high-throughput analytical power. From initial lead screening to final IND support, we ensure your immunotherapy program is built on a foundation of safety.
Contact Our Team for More Information and to Discuss Your Project
Reference
- Gabriel, Kathrin, et al. "The role of cytokines in cytokine release syndrome (CRS) after CAR T cell therapy." Biochimica et Biophysica Acta (BBA)-Molecular Cell Research (2026): 120115. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.1016/j.bbamcr.2026.120115
Download our brochure